TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

Sarah Lilian Pett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.